Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011-2016.

Suaya JA, Gessner BD, Fung S, Vuocolo S, Scaife J, Swerdlow DL, Isturiz RE, Arguedas AG.

Vaccine. 2018 Nov 26;36(49):7479-7486. doi: 10.1016/j.vaccine.2018.10.060. Epub 2018 Oct 24.

2.

Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media.

Liu P, Fang AF, LaBadie RR, Crownover PH, Arguedas AG.

Antimicrob Agents Chemother. 2011 Nov;55(11):5022-6. doi: 10.1128/AAC.00692-11. Epub 2011 Aug 22.

3.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N.

Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72.

4.

Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.

Sáez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, Frenck RW, Falleiros-Carvalho LH, Arguedas AG, Bradley J, Arrieta AC, Wald ER, Pancorbo S, McCracken GH Jr, Marques SR; Trovan menigitis Study Group.

Pediatr Infect Dis J. 2002 Jan;21(1):14-22. Erratum in: Pediatr Infect Dis J 2002 Mar;21(3):270.

PMID:
11791092
5.

Ceftazidime for therapy of children with chronic suppurative otitis media without cholesteatoma.

Arguedas AG, Herrera JF, Faingezicht I, Mohs E.

Pediatr Infect Dis J. 1993 Mar;12(3):246-8. No abstract available.

PMID:
8451104
6.

Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.

Arguedas AG, Stutman HR, Zaleska M, Knupp CA, Marks MI, Nussbaum E.

Am J Dis Child. 1992 Jul;146(7):797-802.

PMID:
1496945
7.

Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media.

Stutman HR, Arguedas AG.

Clin Infect Dis. 1992 Jun;14 Suppl 2:S204-8; discussion S209-11. Review.

PMID:
1617039
8.

In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.

Akaniro JC, Stutman HR, Arguedas AG, Vargas OM.

Antimicrob Agents Chemother. 1992 Feb;36(2):255-61.

9.

Measles.

Arguedas AG, Deveikis AA, Marks MI.

Am J Infect Control. 1991 Dec;19(6):290-8. Review.

PMID:
1763825
10.

Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion.

Arguedas AG, Zaleska M, Stutman HR, Blumer JL, Hains CS.

Pediatr Infect Dis J. 1991 May;10(5):375-80.

PMID:
1906160
11.

In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid.

Arguedas AG, Arrieta AC, Stutman HR, Akaniro JC, Marks MI.

J Antimicrob Chemother. 1991 Mar;27(3):311-8.

PMID:
1903788
12.

In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.

Arguedas AG, Akaniro JC, Stutman HR, Marks MI.

Antimicrob Agents Chemother. 1990 Nov;34(11):2223-7.

Supplemental Content

Loading ...
Support Center